Diadia
Our TechnologyResearchResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResourcesResearch
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

metabolic · Mechanism Report

How does impaired liver insulin signaling affect glucose and lipid production?

Impaired liver insulin signaling reduces suppression of glucose production, while triglyceride synthesis and VLDL output may persist depending on the context.

PlausibleNovember 18, 202610 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

When liver insulin signaling is impaired, insulin inadequately suppresses hepatic glucose production while continuing to support triglyceride synthesis and very-low-density lipoprotein output.

laying out figure…
1 of 3 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

Reduced insulin signaling weakens regulation of glucose production and glycogen metabolism in the liver. Triglyceride synthesis and VLDL output may continue through residual lipid-producing pathways and increased apolipoprotein B availability, but this is not inevitable.

Verified conclusion

Impaired hepatic insulin action is a central feature of obesity, NAFLD, and type 2 diabetes, but its effects on glucose and lipid metabolism are not uniformly coupled.

Clinical and metabolic evidence

  • Human tracer hyperinsulinemic–euglycemic clamp studies show that insulin suppresses endogenous/hepatic glucose production less effectively in obesity and NAFLD, and more severely in type 2 diabetes. Both gluconeogenesis and glycogenolysis can remain inappropriately active at matched insulin exposure.
  • In NAFLD, this impaired glucose-output suppression has occurred alongside reduced insulin-stimulated hepatic insulin receptor–AKT signaling, supporting a hepatic contribution rather than an isolated systemic association.

Mechanistic interpretation

  • Reduced insulin receptor–IRS–PI3K–AKT signaling diminishes AKT-mediated restraint of FOXO1-dependent gluconeogenic transcription and weakens insulin regulation of glycogen metabolism. This provides a coherent mechanism for persistent hepatic glucose release.
  • Lipid handling can be selectively preserved in some settings: residual SREBP-1c-related lipogenic signaling, nutrient-responsive pathways, and fatty-acid re-esterification may maintain triglyceride synthesis despite impaired glucose-regulatory insulin action.
  • Loss of insulin-mediated suppression of apolipoprotein B availability can independently promote VLDL assembly and secretion. Thus, triglyceride-rich VLDL output may reflect both triglyceride substrate supply and greater apoB availability.

Important qualification

  • Continued insulin-supported lipogenesis is not a universal result of impaired hepatic insulin signaling. Experimental disruption of hepatic insulin receptor, IRS1/2, or AKT2 generally reduces SREBP-1c induction, lipogenic gene expression, and hepatic triglyceride accumulation.
  • VLDL output also depends on fatty-acid flux, apoB handling, direct insulin effects on secretion, and peripheral clearance; hepatic triglyceride synthesis alone is insufficient to predict circulating triglycerides.

Bottom line

  • The glucose-production portion of the claim is strongly supported. Persistent triglyceride synthesis and VLDL output are biologically credible—particularly in selective or postreceptor insulin resistance—but are context-dependent rather than an inevitable consequence of impaired liver insulin signaling.

References

  1. Hepatic Insulin Resistance Is Not Pathway Selective in ... - PMC — pmc.ncbi.nlm.nih.gov ↗
  2. Measuring and estimating insulin resistance in clinical ... - PMC — pmc.ncbi.nlm.nih.gov ↗
  3. Obesity and Type 2 Diabetes Impair Insulin-Induced Suppression of Glycogenolysis as Well as Gluconeogenesis — diabetesjournals.org ↗
  4. Hepatic Insulin Resistance Is Not Pathway Selective in Humans With Nonalcoholic Fatty Liver Disease — diabetesjournals.org ↗
  5. Hepatic selective insulin resistance at the intersection of insulin signaling and metabolic dysfunction-associated steatotic liver disease — cell.com ↗
  6. Physiological and pathophysiological actions of insulin in the liver - PMC - NIH — pmc.ncbi.nlm.nih.gov ↗
  7. Research article — pmc.ncbi.nlm.nih.gov ↗
  8. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. — europepmc.org ↗
  9. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice — ncbi.nlm.nih.gov ↗
  10. Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia | Arteriosclerosis, Thrombosis, and Vascular Biology — ahajournals.org ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible2 sourcesCan disrupted sleep and circadian rhythms contribute to insulin resistance?→Plausible4 sourcesCan sustained cortisol excess contribute to insulin resistance?→